Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic...

Area of Science:

• Oncology
• Cell Biology
• Biochemistry

Background:

• Mammalian target of rapamycin (mTOR) is frequently upregulated in glioblastomas.
• Rapamycin, an mTOR inhibitor, shows potential in reducing glioblastoma survival.
• The specific role of mitochondria in rapamycin's therapeutic effect on glioblastoma is not well understood.

Purpose of the Study:

• To investigate the mechanisms of mitochondrial dysfunction induced by mTOR signaling suppression in glioblastoma.
• To evaluate the therapeutic potential of targeting mitochondria in glioblastoma treatment.
• To assess the synergistic effects of rapamycin and temzolomide (TMZ) on glioblastoma viability.

Main Methods:

• Treatment of glioblastoma cells with rapamycin to inhibit mTOR signaling.
• Assessment of apoptosis, transformative potential, and mitochondrial health markers.
• Measurement of reactive oxygen species (ROS) production and mitochondrial membrane potential (MMP).
• Analysis of mitochondrial dynamics.
• Co-treatment experiments with rapamycin and temzolomide (TMZ).

Main Results:

• Rapamycin treatment led to increased apoptosis and reduced transformative potential in glioblastoma cells.
• Significant alterations in mitochondrial health were observed, including increased ROS production and MMP depolarization.
• Mitochondrial dynamics were altered following rapamycin treatment.
• Co-treatment with TMZ and rapamycin demonstrated synergistic effects in suppressing glioblastoma viability.
• The combination therapy enhanced ROS production and MMP depolarization.

Conclusions:

• mTOR inhibition by rapamycin induces mitochondrial dysfunction in glioblastoma.
• Mitochondria represent a viable therapeutic target for glioblastoma treatment.
• Rapamycin and TMZ exhibit a synergistic effect against glioblastoma, underscoring the potential of combination therapies targeting mitochondrial pathways.